A Prospective Longitudinal Multicenter Observational Study to Investigate Neurofilament Light Chain Levels and Patient Satisfaction After Subcutaneous Ocrelizumab Administration in Persons With Multiple Sclerosis
Latest Information Update: 03 Jul 2025
At a glance
- Drugs Ocrelizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms SurfSubQ
- Sponsors Roche
Most Recent Events
- 03 Jun 2025 Planned End Date changed from 26 Sep 2026 to 30 Nov 2026.
- 03 Jun 2025 Planned primary completion date changed from 26 Sep 2026 to 30 Nov 2026.
- 22 Jan 2025 New trial record